Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________to__________ Commission File No. 0-14710 XOMA Corporation (Exact name of registrant as specified in its charter) Delaware 52-2154066 (Sta ...

公司业务模式 - 收购临床前药物特许权，采用投资组合方式扩大特许权头寸数量，专注有潜力且授权给大型合作伙伴的资产[8] - 特许权融资比股权融资更高效，比债务融资负担小，具有成本低、稀释性低等优势[13][14] 市场机会 - 2014 - 2018年行业许可交易共1988笔，其中3期236笔、2期343笔、1期194笔、临床前/其他1215笔[17] 公司交易案例 - XOMA与Agenus、Aronora、Palobiofarma交易，投资分别为1500万美元、900万美元、1000万美元[29][34][38] 公司资产情况 - 资产组合超65个且增长，超60%处于临床阶段，平均特许权费率约2.5%，特许权期限为商业化后8 - 12年[43] - 目前特许权组合覆盖超90%下一代新兴和新型免疫肿瘤学靶点[48][49] 公司财务与战略 - 潜在里程碑价值超10亿美元，不同峰值销售额和特许权费率下资产数量不同[68][71][72][73][74] - 战略需耐心等待药物资产推进和精简基础设施以降低成本[76][78] 公司近期动态与展望 - 自2018年3季度以来特许权许可数量增加40%，2019年从合作伙伴处获1580万美元[80] - 未来将收购更多资产扩大组合，维持低成本基础设施，当前资产负债表可支持多年运营[81]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________to__________ Commission File No. 0-14710 XOMA Corporation (Exact name of registrant as specified in its charter) Delaware 52-2154066 (State or ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR (Exact name of registrant as specified in its charter) Delaware 52-2154066 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) Emeryville, California 94608 (Address of principal executive offices) (Zip Code) Registrant's tele ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 0‑14710 XOMA CORPORATION (Exact name of registrant as specified in its charter) Delaware 52‑2154066 (State or other jurisdiction o ...

Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________to__________ Commission File No. 0-14710 XOMA Corporation (Exact name of registrant as specified in its charter) Delaware 52-2154066 (State or other jurisd ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________to__________ Commission File No. 0-14710 XOMA Corporation (Exact name of registrant as specified in its charter) Delaware 52-2154066 (State or other jurisdictio ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________to__________ Commission File No. 0-14710 XOMA Corporation (Exact name of registrant as specified in its charter) Delaware 52-2154066 (State or other jurisdicti ...

公司概况 - 公司通过组合方式扩大特许权使用费权益数量，专注有潜力成为畅销药的研发阶段资产，目前拥有45项资产且数量在增加[6] 业务模式 - 与传统生物技术公司自行研发不同，公司积累并持有与制药公司合作资产的里程碑和特许权使用费权益，研发成本由合作方承担[9][10] 市场机会 - 2014 - 2018年共有1988笔许可交易，其中3期236笔、2期343笔、1期194笔、临床前及其他1215笔[13] 竞争优势 - 与典型中小型生物技术公司相比，公司资产组合规模为45项，更具多元化，获批概率高，风险回报比为低风险中高回报，且是资金提供者[21] 资产情况 - 超60%的资产处于中期研发阶段，特许权使用费率约3%，期限为商业化后8 - 12年[24] - 资产分布在10多个治疗类别，涵盖肿瘤学、免疫学等[35][36] 潜在收益 - 若合作产品年销售额达10亿美元，公司持有3%特许权使用费，每年可获3000万美元特许权使用费收入及里程碑收入[48] 收购策略 - 收购高潜力、资金充足资产的里程碑和特许权使用许可，专注临床中期资产，合作公司承担开发成本[50] 近期亮点 - 完成2000万美元股权融资，与硅谷银行建立2000万美元信贷额度，以1500万美元收购Agenus公司7项资产权益等[68] 未来展望 - 收购更多资产使资产组合超50项，维持低成本运营，当前资产负债表可支持多年运营，每月核心总务及行政费用100万美元[69] 价值原因 - 公司持有45项资产，合作方承担研发成本，通过行业网络获取特许权权利，构建多元化组合，低成本运营使未来潜在收入多为利润[70]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 0-14710 XOMA CORPORATION (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organizati ...